Fig. 7
miR-27b-3p knockdown mitigated YAP/LOXL2 inhibition efficacy of MSC-ex. A qRT-PCR analysis of miR-27b-3p in negative control inhibitors (NC) or miR-27b-3p inhibitors transfected MSC (n = 6; ***p < .001). B qRT-PCR analysis of miR-27b-3p in exosomes isolated from NC inhibitors transfected MSC (NCin-ex), or miR-27b-3p inhibitors transfected MSC (miR-27bin-ex) (n = 6; ***p < .001). C. FISH analysis of miR-27b-3p in PBS, 200 μg/mL NCin-ex or miR-27bin-ex treated LX-2 cells. Scale bars, 20 µm. D–G qRT-PCR analysis of YAP, LOXL2, α-SMA and Col1A2 mRNA in PBS, 200 μg/mL NCin-ex or miR-27bin-ex treated LX-2 cells (n = 6; ***p < .001). H Western blot analysis and quantification of YAP, LOXL2, α-SMA and Col1A2 protein in PBS, NCin-ex or miR-27bin-ex treated LX-2 cells (n = 4; *p < .05, #p < .05, @@p < .01, and &&p < .01)